A Phase 2/3 interventional study of Melatonin and Quetiapine in Psychiatric Disorders and Insomnia, sponsored by Lone Baandrup. Recruiting at 1 site in Denmark. Open to participants aged 16 Years to 64 Years. Per ClinicalTrials.gov, last updated 2025-04-24.
Sponsored by Lone Baandrup · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies testing melatonin in Sleep Initiation and Maintenance Disorders — 8 open to participants now, 8 under way, 2 of them phase 3. Melatonin · Sleep Initiation and Maintenance Disorders.
Among the 25 studies testing melatonin in Sleep Initiation and Maintenance Disorders, this one is the 3rd largest by planned enrollment, is one of 2 that started in 2023, is one of 3 in phase 2/3, and was the 15th registered.
2,734 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 733 are open to participants now.
Browse Sleep Initiation and Maintenance Disorders studies →8 of the 25 studies testing melatonin in Sleep Initiation and Maintenance Disorders are open now, in 6 countries. Recruiting first, the newest first:
The University of Hong Kong · Sites in Hong Kong
Ages 60+
Emory University · Sites in United States
Ages 18–65
Weill Medical College of Cornell University · Sites in United States
Ages 18+
Woolcock Institute of Medical Research · Sites in Australia
Ages 55+
Woolcock Institute of Medical Research · Sites in Australia
Ages 55+
By country, each count listing its studies:
Melatonin: first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 392 Sleep Initiation and Maintenance Disorders studies recruiting now, 155 (40%) set no upper age limit and 207 (53%) stop at 75 or younger; 59 take children under 18; 110 take healthy volunteers.
This study: 16 Years to 64 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 7 · Phase 3 6 · Phase 4 3
First in 1995; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 255 is above the median of 68 across 2,359 interventional studies indexed under Sleep Initiation and Maintenance Disorders.
Median enrollment 59 across the 25 interventional studies. Of the 14 that completed or were terminated, 5 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 25 have an industry lead sponsor. The 10 most frequent:
Lone Baandrup is the lead sponsor of 4 studies on the registry; 2 are open to participants now.
Lone Baandrup has 1 study filed under Sleep Initiation and Maintenance Disorders — fewer than ten, so there is no comparison to draw.
3 of the studies testing melatonin in Sleep Initiation and Maintenance Disorders that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07336277Phase 3Emory UniversitySleep Quality and the Efficacy of a Multimodal Sleep Pathway in Hospitalized Orthopedic Trauma Patients | 2027-07 |
| NCT07046429Weill Medical College of Cornell UniversityAffect of Melatonin on Sleep and Cognition in Cirrhosis | 2026-12-31 |
| NCT07737665Mahidol UniversityEfficacy of Melatonin Treatment on Sleep Quality Improvement in Inflammatory Bowel Disease Patients With Clinical Remission | 2027-04-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 25 studies testing melatonin in Sleep Initiation and Maintenance Disorders, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this investigator-initiated, randomized, blinded, 3-armed placebo-controlled, pragmatic, clinical superiority trial is to examine the efficacy of melatonin or low-dose quetiapine versus placebo for treatment of insomnia in patients with psychiatric disorders. The aims of the study are:
Participants will receive six weeks of treatment with either melatonin, quetiapine or placebo followed by a brief taper off.
2,734 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 733 are open to participants now.
This study's planned enrollment of 255 is above the median of 68 across 2,359 interventional studies indexed under Sleep Initiation and Maintenance Disorders.
Browse Sleep Initiation and Maintenance Disorders studies →Lone Baandrup is the lead sponsor of 4 studies on the registry; 2 are open to participants now.
Compared within Sleep Initiation and Maintenance Disorders, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Mental Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Melatonin
Drug: Quetiapine
Drug: Placebo
3-9 mg flexible dosing before bed time
50-150 mg flexible dosing before bed time
1-3 capsules flexible dosing before bed time
Insomnia severity
Insomnia Severity Index, range 0-28, higher is worse
Time frame: 6 weeks
Clinical global impression (CGI)
Clinical global impression: Severity, range 0-7, higher is worse
Time frame: 6 weeks
Subjective sleep quality
Pittsburgh Sleep Quality Index, range 0-21, higher is worse
Time frame: 6 weeks
Psychosocial functioning
Personal and Social Performance Scale, range 1-100, higher is better
Time frame: 6 weeks
Patient-reported subjective well-being
WHO-5 well-being index, range 0-100, higher is better
Time frame: 6 weeks
Objective sleep quality (polysomnography)
Total sleep time in minutes, higher is better
Time frame: 6 weeks
Circadian rhythmicity (actigraphy)
Interdaily stability which quantifies the invariability from day to day, i.e., the predictability of the 24 h rest-activity pattern. This index will be 1 for perfect interdaily stability and thus lower values reflect higher variability between the observed days
Time frame: 6 weeks
Plan to share: Yes — Individual participant data will be available for meta-analysis. Proposals should be directed to: lone.baandrup@regionh.dk. To gain access, data requestors will need to sign a data access agreement.
Supporting information: Study protocol, Statistical analysis plan
Time frame: After publication of planned primary, secondary and exploratory outcomes. There will be no end date for availability of data.
Access criteria: Meta-analytical purposes
No publications or documents are linked to this record.
Started Sep 2023 (actual). Primary completion is estimated for Feb 2029, 65 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Melatonin · Quetiapine
Sleep Initiation and Maintenance Disorders →
Lone Baandrup